{"id":"escalation-therapies-group","safety":{"commonSideEffects":[{"rate":"null","effect":"Immune-related adverse events"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This approach allows for a more tailored and effective treatment plan, as the intensity of the therapy can be adjusted based on the individual's response. The goal is to maximize the therapeutic benefit while minimizing potential side effects.","oneSentence":"Escalation Therapies Group involves gradually increasing the intensity of a treatment to achieve a desired therapeutic effect.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:29:35.639Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of various cancers"}]},"trialDetails":[{"nctId":"NCT07444814","phase":"PHASE1","title":"Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Whitehawk Therapeutics, Inc.","startDate":"2025-12-19","conditions":"Endometrial Cancer, Ovarian Cancer, Ovarian Cancer Metastatic","enrollment":226},{"nctId":"NCT06902246","phase":"PHASE2","title":"Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"University of Miami","startDate":"2026-05-01","conditions":"Unresectable Hepatocellular Carcinoma, Hepatocellular Carcinoma","enrollment":30},{"nctId":"NCT07369856","phase":"NA","title":"Spot Analysis of Natriuresis to Guide up- or Down-titration of Diuretic Therapy in Ambulatory Patients With Chronic Heart Failure","status":"RECRUITING","sponsor":"Cardiology Research UBC","startDate":"2025-11-04","conditions":"Heart Failure, Diuretics","enrollment":300},{"nctId":"NCT07424547","phase":"PHASE1","title":"Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors","status":"RECRUITING","sponsor":"Conjupro Biotherapeutics, Inc.","startDate":"2026-03-03","conditions":"Cancer, Solid Tumor Cancer, Advanced Metastatic Cancer","enrollment":386},{"nctId":"NCT01846390","phase":"PHASE1","title":"Romidepsin, Gemcitabine, Dexamethasone and Cisplatin in the Treatment of Peripheral T-Cell and Diffuse Large B-Cell Lymphoma","status":"COMPLETED","sponsor":"Canadian Cancer Trials Group","startDate":"2013-10-01","conditions":"Peripheral T-Cell Lymphoma, Diffuse Large B-Cell Lymphoma","enrollment":21},{"nctId":"NCT07466238","phase":"NA","title":"HAIC Plus Systemic Therapy as De-escalation Therapy Strategy for Biliary Tract Cancer","status":"NOT_YET_RECRUITING","sponsor":"Peking University","startDate":"2026-03-15","conditions":"Biliary Tract Cancer (BTC)","enrollment":40},{"nctId":"NCT05454566","phase":"PHASE1, PHASE2","title":"A Study Evaluating the Safety, Tolerability, and Activity of ICM-203 in Subjects With Knee Osteoarthritis.","status":"NOT_YET_RECRUITING","sponsor":"ICM Co. Ltd.","startDate":"2026-11-15","conditions":"Osteoarthritis, Knee","enrollment":18},{"nctId":"NCT07361874","phase":"NA","title":"IMPACT-MACS: Adrenalectomy vs Semaglutide for Metabolic Outcomes in Mild Autonomous Cortisol Secretion","status":"RECRUITING","sponsor":"University of Texas Southwestern Medical Center","startDate":"2026-03-05","conditions":"Mild Autonomous Cortisol Secretion (MACS), Autonomous Cortisol Secretion (ACS), Subclinical Cushing's","enrollment":75},{"nctId":"NCT07492771","phase":"PHASE1","title":"MP101 in Adults With Acute Pseudomonas Aeruginosa Pneumonia","status":"NOT_YET_RECRUITING","sponsor":"MicrobiotiX Co., Ltd","startDate":"2026-03","conditions":"Pneumonia - Bacterial, Pseudomonas Aeruginosa Infection","enrollment":18},{"nctId":"NCT07414394","phase":"PHASE3","title":"Tigulixostat (IBI128) vs Febuxostat in Gout","status":"RECRUITING","sponsor":"Innovent Biologics Technology Limited (Shanghai R&D Center)","startDate":"2026-03-17","conditions":"Gout","enrollment":600},{"nctId":"NCT07492563","phase":"","title":"Safety and Effectiveness of Tirzepatide in Patients With Obesity at Hospital de Clínicas, Paraguay","status":"NOT_YET_RECRUITING","sponsor":"LABORATORIOS INDUFAR","startDate":"2026-03","conditions":"Obesity, Type 2 Diabetes Mellitus, Overweight With Comorbidities","enrollment":300},{"nctId":"NCT06166836","phase":"PHASE1, PHASE2","title":"a Study to Evaluate the Safety and Efficacy of D-1553 Combined With IN10018 in KRAS G12C Mutant Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"InxMed (Shanghai) Co., Ltd.","startDate":"2022-10-12","conditions":"Solid Tumor","enrollment":140},{"nctId":"NCT01783587","phase":"PHASE1","title":"Safety Study of Afatinib and Postoperative Radiation Therapy to Treat Head and Neck Cancer","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2013-02","conditions":"Squamous Cell Carcinoma of the Head and Neck","enrollment":29},{"nctId":"NCT06476639","phase":"PHASE3","title":"A Phase III Randomised Clinical Trial of Ultrasound Groin Monitoring Versus Groin Lymph Node Dissection to De-Escalate the Extent of Surgery in Vulvar Cancer","status":"NOT_YET_RECRUITING","sponsor":"Queensland Centre for Gynaecological Cancer","startDate":"2026-06-01","conditions":"Vulvar Cancer Stage I, Vulvar Cancer Stage II, Lymph Node Metastasis","enrollment":640},{"nctId":"NCT05936359","phase":"PHASE1","title":"A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms","status":"RECRUITING","sponsor":"Incyte Corporation","startDate":"2023-09-25","conditions":"Myeloproliferative Neoplasms","enrollment":225},{"nctId":"NCT01445509","phase":"PHASE1","title":"Dasatinib in Combination With Bevacizumab to Treat Advanced Solid Tumors","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2008-12-29","conditions":"Solid Tumors","enrollment":50},{"nctId":"NCT06313593","phase":"PHASE1","title":"A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative Neoplasms","status":"RECRUITING","sponsor":"Incyte Corporation","startDate":"2024-08-08","conditions":"Myeloproliferative Neoplasms","enrollment":186},{"nctId":"NCT07481942","phase":"","title":"Body Composition Assessment in Transgender Population.","status":"COMPLETED","sponsor":"Celia Bañuls","startDate":"2017-01-01","conditions":"Transgender","enrollment":70},{"nctId":"NCT06934915","phase":"EARLY_PHASE1","title":"Prednisone in Adults With an Immune-Mediated Subtype of Autism Spectrum Disorder","status":"NOT_YET_RECRUITING","sponsor":"Christopher John McDougle, M.D.","startDate":"2026-11","conditions":"Autism Spectrum Disorder, Autism Spectrum Disorders, Autistic Disorder","enrollment":32},{"nctId":"NCT02287311","phase":"PHASE1","title":"Most Closely Matched 3rd Party Rapidly Generated LMP, BARF1 And EBNA1 Specific CTL, EBV-Positive Lymphoma (MABEL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Baylor College of Medicine","startDate":"2015-02","conditions":"Hodgkin Disease, Non-Hodgkin Lymphoma, Severe Chronic Active Epstein Barr Virus","enrollment":38},{"nctId":"NCT07355868","phase":"EARLY_PHASE1","title":"Treatment of Chronic Obstructive Pulmonary Disease (COPD) by REGEND007 Cell Therapy","status":"RECRUITING","sponsor":"Regend Therapeutics","startDate":"2026-03-19","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":12},{"nctId":"NCT07426055","phase":"PHASE2, PHASE3","title":"PRO-BOOST-LC: Whole-Gland Boost Strategies Versus SBRT Monotherapy in PSMA-Staged Localized and Locally Advanced Prostate Cancer","status":"RECRUITING","sponsor":"Affidea Nu-med Center of Oncological DIagnostics and Therapy","startDate":"2026-03-19","conditions":"Prostate Cancer (Adenocarcinoma), Prostate Brachytherapy, Stereotactic Body Radiation Therapy (SBRT)","enrollment":1200},{"nctId":"NCT07487051","phase":"","title":"THRIVE in Sedated Gastrointestinal Endoscopy","status":"COMPLETED","sponsor":"Fatih Sultan Mehmet Training and Research Hospital","startDate":"2025-07-01","conditions":"Hypoxemia, Gastrointestinal Endoscopy","enrollment":222},{"nctId":"NCT07484932","phase":"NA","title":"TRTRM (ACTTOP) -Guided Dosing Strategy in Older Patients With Cancer","status":"NOT_YET_RECRUITING","sponsor":"The University of Hong Kong","startDate":"2026-05-01","conditions":"Cancer (Solid Tumors), Geriatric Oncology","enrollment":400},{"nctId":"NCT07486700","phase":"PHASE1","title":"The Phase I Study of SIG001 Antibody on Cancer Therapy.","status":"NOT_YET_RECRUITING","sponsor":"Peking University","startDate":"2026-03","conditions":"Neoplams","enrollment":66},{"nctId":"NCT07481058","phase":"PHASE2","title":"KC1036 in Combination With PD-1 Antibody and Platinum-based Chemotherapy for First-line Advanced Esophageal Cancer","status":"RECRUITING","sponsor":"Beijing Konruns Pharmaceutical Co., Ltd.","startDate":"2025-12-12","conditions":"Esophageal Squamous Cell Carcinoma (ESCC)","enrollment":60},{"nctId":"NCT07486726","phase":"PHASE1, PHASE2","title":"Aclarubicin Plus With Azacitidine and Venetoclax in the Treatment of Acute Myeloid Leukemia","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2026-03-15","conditions":"Acute Myeloid Leukemia (AML), Relapse Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia (AML)","enrollment":112},{"nctId":"NCT07182227","phase":"PHASE1, PHASE2","title":"PS-002 for the Treatment of IgA Nephropathy in Adults","status":"RECRUITING","sponsor":"Purespring Therapeutics Limited","startDate":"2026-02","conditions":"Immunoglobulin A (IgA) Nephropathy","enrollment":32},{"nctId":"NCT07380984","phase":"PHASE2","title":"PD-1 Antibody-based Therapy With Concurrent RT for Early-stage NKTCL","status":"RECRUITING","sponsor":"Ruijin Hospital","startDate":"2026-03","conditions":"Natural Killer/T-cell Lymphoma","enrollment":47},{"nctId":"NCT06898450","phase":"PHASE1, PHASE2","title":"A Study to Assess the Safety, Tolerability, and Efficacy of NDI-219216 in Patients With Advanced Solid Tumors.","status":"RECRUITING","sponsor":"Nimbus Wadjet, Inc.","startDate":"2025-03-31","conditions":"Advanced Solid Tumors Cancer, MSI-H Cancer","enrollment":134},{"nctId":"NCT06750289","phase":"PHASE3","title":"Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA Treatment","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-03-28","conditions":"Eosinophilic Asthma","enrollment":400},{"nctId":"NCT06052306","phase":"PHASE1","title":"A Study to Learn How Safe the Study Treatment Actinium-225-macropa-pelgifatamab (BAY3546828) is, How it Affects the Body, How it Moves Into, Through and Out of the Body, and About Its Anticancer Activity in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bayer","startDate":"2023-09-20","conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":232},{"nctId":"NCT05361668","phase":"PHASE2","title":"Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome","status":"COMPLETED","sponsor":"Crinetics Pharmaceuticals Inc.","startDate":"2022-04-22","conditions":"Carcinoid Syndrome, Carcinoid, Carcinoid Tumor","enrollment":36},{"nctId":"NCT02789228","phase":"PHASE1","title":"Research Study Utilizing Expanded Multi-antigen Specific Lymphocytes for the Treatment of Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's National Research Institute","startDate":"2016-10-12","conditions":"Solid Tumors","enrollment":28},{"nctId":"NCT07483398","phase":"PHASE4","title":"RELIEF-PD: Crisugabalin for Nociplastic Pain in Parkinson's Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Guangdong Provincial People's Hospital","startDate":"2026-03-13","conditions":"Parkinson's Disease With Nociceptive Pain","enrollment":166},{"nctId":"NCT05828511","phase":"PHASE1, PHASE2","title":"A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2023-12-19","conditions":"Multiple Myeloma","enrollment":149},{"nctId":"NCT05727189","phase":"PHASE1","title":"A Study of Idazoxan in Healthy Participants","status":"ACTIVE_NOT_RECRUITING","sponsor":"Terran Biosciences Australia Pty Ltd","startDate":"2023-02-14","conditions":"Healthy","enrollment":150},{"nctId":"NCT07476846","phase":"NA","title":"rhTPO Dose Escalation vs Eltrombopag Switch in ITP","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2026-03","conditions":"Primary Immune Thrombocytopenia (ITP)","enrollment":112},{"nctId":"NCT05909527","phase":"PHASE1, PHASE2","title":"A Clinical Study of CAR-T Treating Relapsed or Refractory T Cell Lymphoblastic Acute Leukemia/ Lymphoma","status":"WITHDRAWN","sponsor":"Guangzhou Bio-gene Technology Co., Ltd","startDate":"2023-05-01","conditions":"T-Cell Acute Lymphocytic Leukemia","enrollment":""},{"nctId":"NCT04077463","phase":"PHASE1","title":"A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2019-09-04","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":701},{"nctId":"NCT07476378","phase":"NA","title":"A Study to Evaluate MTM-H-001 Injection in Adult Participants With Relapsed or Refractory B-cell Malignancies","status":"NOT_YET_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2026-03","conditions":"Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma, Follicular, Lymphoma, Mantle-Cell","enrollment":69},{"nctId":"NCT07353398","phase":"EARLY_PHASE1","title":"Early-phase Study of ART002g1 Injection in HeFH: Safety, Tolerability and Preliminary Efficacy","status":"NOT_YET_RECRUITING","sponsor":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2026-03-11","conditions":"Heterozygous Familial Hypercholesterolemia","enrollment":24},{"nctId":"NCT06927297","phase":"PHASE1","title":"Phase I Study of the Safety, Tolerability, and Efficacy of an Engineered Mitochondrial Vaccine in Advanced Solid Tumors","status":"RECRUITING","sponsor":"West China Hospital","startDate":"2025-05-09","conditions":"Advanced Solid Tumor Malignancies, Advanced Solid Malignancies","enrollment":12},{"nctId":"NCT06034002","phase":"PHASE1","title":"A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms","status":"RECRUITING","sponsor":"Incyte Corporation","startDate":"2023-12-04","conditions":"Myeloproliferative Neoplasms","enrollment":230},{"nctId":"NCT03600883","phase":"PHASE1, PHASE2","title":"A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Amgen","startDate":"2018-08-27","conditions":"KRAS p.G12C Mutant Advanced Solid Tumors","enrollment":713},{"nctId":"NCT04042935","phase":"PHASE1","title":"Alpha Lipoic Acid to Decrease Pain and Side Effects in Concurrent Treatment of HNSCC","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2020-02-27","conditions":"HNSCC","enrollment":5},{"nctId":"NCT04588922","phase":"PHASE1, PHASE2","title":"Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML","status":"RECRUITING","sponsor":"Sellas Life Sciences Group","startDate":"2021-05-10","conditions":"Hematologic Malignancies","enrollment":160},{"nctId":"NCT07258407","phase":"PHASE1, PHASE2","title":"A Clinical Trial Evaluating the Safety of TD001 In Patients With PSMA-Expressing Metastatic Prostate Cancer","status":"RECRUITING","sponsor":"T.O.A.D. Oncology SA","startDate":"2026-01-30","conditions":"Metastatic Castration-Resistant Prostatic Cancer","enrollment":180},{"nctId":"NCT07470853","phase":"PHASE1","title":"A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.","status":"RECRUITING","sponsor":"Whitehawk Therapeutics, Inc.","startDate":"2026-03-15","conditions":"PROC, Platinum Resistant Ovarian Cancer, Endometrial Cancer","enrollment":265},{"nctId":"NCT07463235","phase":"PHASE3","title":"Safety and Potency of a High Cabergoline Dosage in Microprolactinomas","status":"RECRUITING","sponsor":"University of Sao Paulo General Hospital","startDate":"2026-03-04","conditions":"Prolactinoma, Prolactin Excess","enrollment":70},{"nctId":"NCT05935098","phase":"PHASE1","title":"BGB-A3055 Alone and in Combination With Tislelizumab in Participants With Solid Tumors","status":"TERMINATED","sponsor":"BeiGene","startDate":"2023-08-21","conditions":"Advanced Solid Tumor, Metastatic Solid Tumor, Solid Tumor","enrollment":99},{"nctId":"NCT07436988","phase":"PHASE1","title":"Affordable Made-in-India Microspheres for Liver Cancer Therapy","status":"NOT_YET_RECRUITING","sponsor":"Post Graduate Institute of Medical Education and Research, Chandigarh","startDate":"2026-02-15","conditions":"Hepatecellular Carcinoma","enrollment":18},{"nctId":"NCT04939610","phase":"PHASE1, PHASE2","title":"A Study of 177Lu-FAP-2286 in Advanced Solid Tumors","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2021-07-30","conditions":"Solid Tumor","enrollment":222},{"nctId":"NCT07463677","phase":"PHASE2","title":"Tunlametinib Combination Therapy in KRAS-Mutated Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-03-15","conditions":"Lung Cancer (NSCLC)","enrollment":55},{"nctId":"NCT07448298","phase":"EARLY_PHASE1","title":"A Clinical Study of AFN50 in the Treatment of Autoimmune Diseases","status":"RECRUITING","sponsor":"Beijing Boren Hospital","startDate":"2026-03-09","conditions":"Relapsed/Refractory Autoimmune Diseases","enrollment":18},{"nctId":"NCT05514132","phase":"PHASE1","title":"A Study to Evaluate the Safety and Pharmacokinetics of Ceralasertib in Combination With Durvalumab in Chinese Patients With Advanced Solid Tumours","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2022-09-23","conditions":"Advanced Solid Tumours","enrollment":14},{"nctId":"NCT06951646","phase":"PHASE2","title":"ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immunotherapy (CR1STAL-Adaptive)","status":"RECRUITING","sponsor":"Second Xiangya Hospital of Central South University","startDate":"2026-03-10","conditions":"Non Small Cell Lung Cancer, Immune Checkpoint Inhibitors (ICIs)","enrollment":70},{"nctId":"NCT06820320","phase":"PHASE2","title":"Oral Iohexol in the Management of Chylous Ascites After After Retroperitoneal or Extended Lymphadenectomy","status":"COMPLETED","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2025-02-15","conditions":"Chylous Ascites, Abdominal Neoplasm, Pelvic Neoplasms","enrollment":42},{"nctId":"NCT07443826","phase":"PHASE1, PHASE2","title":"CALM-AF-AI: Counteracting Age-related Loss of Muscle With AAV-Follistatin Combined With Angiogenesis-Inducing VEGF Plasmid Gene Therapy","status":"RECRUITING","sponsor":"Unlimited Biotechnology LLC","startDate":"2026-03-31","conditions":"Age-related Muscle Decline","enrollment":12},{"nctId":"NCT07454083","phase":"","title":"Real-World Study of Acupuncture for Pain Control","status":"NOT_YET_RECRUITING","sponsor":"Qi's Clinic","startDate":"2026-03-21","conditions":"Non-Cancer Pain,Musculoskeletal Pain,Chronic Pain,Acute Pain","enrollment":300},{"nctId":"NCT07232732","phase":"PHASE1","title":"A Study of LY3549492 in Healthy Participants and Participants With Overweight or Obesity","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2025-10-27","conditions":"Healthy, Obesity, Overweight","enrollment":120},{"nctId":"NCT07083154","phase":"PHASE3","title":"GLP-1/GCG Dual Agonist in Type 2 Diabetes With Early Dementia (LIGHT-COG Study)","status":"RECRUITING","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2025-09-27","conditions":"Dementia, Mild, Mild Cognitive Impairment, Type 2 Diabetes","enrollment":420},{"nctId":"NCT05526924","phase":"PHASE1","title":"Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck Cancer","status":"RECRUITING","sponsor":"University of Chicago","startDate":"2023-03-07","conditions":"Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Head and Neck Carcinoma","enrollment":30},{"nctId":"NCT07401836","phase":"NA","title":"Standardized Sleep Bundle for Cardiac Surgery Patients","status":"NOT_YET_RECRUITING","sponsor":"Horizon Health Network","startDate":"2026-03","conditions":"Sleep","enrollment":20},{"nctId":"NCT05463848","phase":"PHASE2","title":"Surgical Pembro +/- Olaparib w TMZ for rGBM","status":"RECRUITING","sponsor":"L. Nicolas Gonzalez Castro, MD, PhD","startDate":"2022-10-21","conditions":"Glioblastoma, Recurrent Glioblastoma","enrollment":78},{"nctId":"NCT07284069","phase":"EARLY_PHASE1","title":"Senicapoc and Perampanel for Newly Diagnosed Glioblastoma","status":"RECRUITING","sponsor":"Aarhus University Hospital","startDate":"2026-03-01","conditions":"Glioblastoma","enrollment":36},{"nctId":"NCT05453695","phase":"PHASE1","title":"Intravenous DNase I for the Treatment of Sepsis (IDEALSepsisI)","status":"RECRUITING","sponsor":"McMaster University","startDate":"2023-01-17","conditions":"Sepsis, Critical Illness","enrollment":36},{"nctId":"NCT07446725","phase":"PHASE1, PHASE2","title":"A Study to Evaluate Safety, PK and Efficacy of GH55 in Combination With GH21 in Patients With Solid Tumors","status":"NOT_YET_RECRUITING","sponsor":"Suzhou Genhouse Bio Co., Ltd.","startDate":"2026-02-24","conditions":"Advanced Solid Tumor Cancer","enrollment":152},{"nctId":"NCT06880081","phase":"PHASE1","title":"Study of PN20 in Adult Patients With Primary Immune Thrombocytopenia (ITP)","status":"RECRUITING","sponsor":"Chongqing Peg-Bio Biopharm Co., Ltd.","startDate":"2025-03-07","conditions":"Primary Immune Thrombocytopenia (ITP)","enrollment":12},{"nctId":"NCT07441954","phase":"PHASE1, PHASE2","title":"Pomalidomide Combined With Obinutuzumab in the Treatment of Patients With Relapsed/Refractory Indolent Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2026-03-20","conditions":"Indolent Lymphoma","enrollment":53},{"nctId":"NCT04077723","phase":"PHASE1, PHASE2","title":"A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2019-08-13","conditions":"Lymphoma, Non-Hodgkin","enrollment":498},{"nctId":"NCT07236801","phase":"PHASE1","title":"Exploratory Clinical Study on YTS109 Cell Therapy for Autoimmune Diseases","status":"RECRUITING","sponsor":"China Immunotech (Beijing) Biotechnology Co., Ltd.","startDate":"2025-11-13","conditions":"Systemic Lupus Erythematosus (SLE), Systemic Sclerosis, Sjogren's Syndrome (SS)","enrollment":18},{"nctId":"NCT06465199","phase":"PHASE1, PHASE2","title":"Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas","status":"RECRUITING","sponsor":"Milton S. Hershey Medical Center","startDate":"2026-03-28","conditions":"Atypical Teratoid/Rhabdoid Tumor, Embryonal Tumor With Multilayered Rosettes, Ewing Sarcoma","enrollment":289},{"nctId":"NCT07123519","phase":"PHASE1","title":"A Clinical Study of YTS109 Cells for the Treatment of R/R Autoimmune Diseases","status":"RECRUITING","sponsor":"China Immunotech (Beijing) Biotechnology Co., Ltd.","startDate":"2025-08-13","conditions":"Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN), Sjogren&#39;s Syndrome (SS)","enrollment":18},{"nctId":"NCT06736418","phase":"PHASE1","title":"Study of 225Ac-ABD147 to Establish Optimal Dose in Patients With SCLC and LCNEC of the Lung That Previously Received Platinum-based Chemotherapy","status":"RECRUITING","sponsor":"Abdera Therapeutics Inc.","startDate":"2025-03-10","conditions":"Small-Cell Lung Cancer (SCLC), Large Cell Neuroendocrine Carcinoma of the Lung","enrollment":65},{"nctId":"NCT05765812","phase":"PHASE1, PHASE2","title":"A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma","status":"RECRUITING","sponsor":"Debiopharm International SA","startDate":"2023-05-15","conditions":"Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype, Astrocytoma, Grade III","enrollment":116},{"nctId":"NCT07438340","phase":"NA","title":"Managing Aggression: Effectiveness of Model-Based Standardized Patient Simulation","status":"NOT_YET_RECRUITING","sponsor":"Yuksek Ihtisas University","startDate":"2026-02","conditions":"Aggression","enrollment":56},{"nctId":"NCT04752774","phase":"PHASE1, PHASE2","title":"A Study to Assess the Safety and Efficacy of IPN10200 in Adult Participants With Upper Limb Spasticity.","status":"RECRUITING","sponsor":"Ipsen","startDate":"2021-04-29","conditions":"Spasticity","enrollment":240},{"nctId":"NCT05603910","phase":"PHASE1","title":"Phase 1 Clinical Trial of Lenvatinib, Pembrolizumab and Hypofractionated Pelvic Radiation Therapy for pMMR Recurrent/Unresectable Endometrial Carcinoma","status":"RECRUITING","sponsor":"Aaron Wolfson","startDate":"2023-04-15","conditions":"Recurrent Endometrial Carcinoma, Unresectable Endometrial Carcinoma","enrollment":18},{"nctId":"NCT06625060","phase":"PHASE2","title":"A Study to Evaluate IPN10200 Safety and Efficacy in the Prevention of Episodic or Chronic Migraine in Adults","status":"RECRUITING","sponsor":"Ipsen","startDate":"2024-10-10","conditions":"Episodic Migraine, Chronic Migraine","enrollment":641},{"nctId":"NCT03248258","phase":"","title":"Enhancing Shared Decision-Making in Metastatic Breast Cancer (Qualitative Study)","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","startDate":"2017-06-27","conditions":"Decision Making ,Shared, De-escalation","enrollment":200},{"nctId":"NCT06520397","phase":"PHASE4","title":"Efficacy and Safety of Dual-targeted Therapy With Upadacitinib and Ustekinumab Versus Intensified Ustekinumab Therapy in Crohn's Disease","status":"RECRUITING","sponsor":"Sixth Affiliated Hospital, Sun Yat-sen University","startDate":"2024-07-15","conditions":"Crohn Disease","enrollment":214},{"nctId":"NCT06627244","phase":"PHASE2","title":"Study of Tebentafusp and Radioembolization in the Treatment of Metastatic Uveal Melanoma","status":"RECRUITING","sponsor":"University of Miami","startDate":"2025-02-14","conditions":"Metastatic Uveal Melanoma, Metastatic Uveal Melanoma in the Liver","enrollment":30},{"nctId":"NCT02264678","phase":"PHASE1, PHASE2","title":"Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2014-10-31","conditions":"Adv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, Gastric, Breast and Ovarian Cancer","enrollment":357},{"nctId":"NCT06264167","phase":"NA","title":"NODE (groiN ultrasOunD cancEr)","status":"RECRUITING","sponsor":"Queensland Centre for Gynaecological Cancer","startDate":"2024-07-01","conditions":"Vulvar Cancer Stage Ib, Vulvar Cancer Stage II, Lymph Node Metastasis","enrollment":30},{"nctId":"NCT03866187","phase":"PHASE1, PHASE2","title":"Safety, Efficacy, Immunogenicity Study of GSK Biologicals' HBV Viral Vector and Adjuvanted Proteins Vaccine (GSK3528869A) in Adult Patients With Chronic Hepatitis B Infection","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2019-03-28","conditions":"Hepatitis B, Chronic","enrollment":236},{"nctId":"NCT05720130","phase":"PHASE1, PHASE2","title":"Phase Ib/IIa Dose Escalation and Expansion Study of [²¹²Pb]Pb-ADVC001 in Metastatic Prostate Cancer (TheraPb - Phase I/II Study).","status":"RECRUITING","sponsor":"AdvanCell Pty Limited","startDate":"2023-03-15","conditions":"Prostate Cancer, Metastatic Castration-resistant Prostate Cancer, Metastatic Hormone Sensitive Prostate Cancer","enrollment":100},{"nctId":"NCT07422896","phase":"PHASE1","title":"A Phase I First-in-human Trial of Bvax (B-cell Vaccination) in Addition to Standard of Care Chemoradiotherapy for Newly Diagnosed Glioblastoma","status":"NOT_YET_RECRUITING","sponsor":"Catalina Lee Chang","startDate":"2026-06-01","conditions":"Glioblastoma","enrollment":25},{"nctId":"NCT02659930","phase":"PHASE1","title":"Pomalidomide in Combination With Liposomal Doxorubicin in People With Advanced or Refractory Kaposi Sarcoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2016-01-13","conditions":"Kaposi Sarcoma","enrollment":62},{"nctId":"NCT06515002","phase":"PHASE1, PHASE2","title":"A Study to Test How Well BI 3720931 is Tolerated and Whether it Improves Lung Function in People With Cystic Fibrosis (Lenticlair™ 1)","status":"TERMINATED","sponsor":"Boehringer Ingelheim","startDate":"2024-11-04","conditions":"Cystic Fibrosis","enrollment":5},{"nctId":"NCT06902896","phase":"PHASE1","title":"Safety and Efficacy of FAP iCDC in End-stage Dilated Cardiomyopathy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2025-04-22","conditions":"Dilated Cardiomyopathy (DCM), Heart Failure","enrollment":9},{"nctId":"NCT03051464","phase":"PHASE2, PHASE3","title":"No Surgery Trial / Two Dose-escalation Strategies","status":"RECRUITING","sponsor":"Sir Mortimer B. Davis - Jewish General Hospital","startDate":"2017-04-25","conditions":"Stage II Rectal Cancer","enrollment":131},{"nctId":"NCT05100251","phase":"PHASE1","title":"Clinical Trial of WBC100 on Advanced Solid Tumor","status":"TERMINATED","sponsor":"Zhejiang University","startDate":"2021-12-17","conditions":"Solid Tumor","enrollment":68},{"nctId":"NCT05879978","phase":"PHASE1","title":"A Study to Test How Well Different Doses of Obrixtamig (BI 764532) in Combination With Ezabenlimab Are Tolerated by People With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3","status":"ACTIVE_NOT_RECRUITING","sponsor":"Boehringer Ingelheim","startDate":"2023-06-27","conditions":"Small Cell Lung Carcinoma (SCLC), Neuroendocrine Neoplasms","enrollment":45},{"nctId":"NCT07416032","phase":"EARLY_PHASE1","title":"A Clinical Study Evaluating the Safety and Preliminary Efficacy of Universal Allogeneic CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C)in Patients With Refractory Primary Immune Thrombocytopenia","status":"NOT_YET_RECRUITING","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2026-02-20","conditions":"Immune Thrombocytopenia (ITP)","enrollment":27},{"nctId":"NCT07169279","phase":"PHASE2","title":"Interventional Study of Infigratinib in Children < 3 Years Old With Achondroplasia (ACH)","status":"RECRUITING","sponsor":"QED Therapeutics, a BridgeBio company","startDate":"2025-11-19","conditions":"Achondroplasia","enrollment":77},{"nctId":"NCT07413042","phase":"PHASE1","title":"A Phase I Study to Evaluate the Safety and Preliminary Efficacy of [225Ac]Ac-DOTATATE Injection Combined With Tislelizumab in the Maintenance Treatment Period for Patients of Extensive-stage Small Cell Lung Cancer (ES-SCLC) With Somatostatin Receptors (SSTR)+ as First-line Treatment","status":"RECRUITING","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2026-01-20","conditions":"SCLC, Extensive Stage","enrollment":24},{"nctId":"NCT07406477","phase":"PHASE2","title":"The PROTECT-HIE Trial","status":"NOT_YET_RECRUITING","sponsor":"University of Alberta","startDate":"2026-05-01","conditions":"Hypoxic-ischemic Encephalopathy (HIE)","enrollment":40},{"nctId":"NCT07408544","phase":"","title":"Clinical Efectiveness of a Multiplex PCR-Based Rapid Diagnostic Method in Bloodstream Infections","status":"RECRUITING","sponsor":"Istanbul Medipol University Hospital","startDate":"2026-01-01","conditions":"Bloodstream Infections, Bacteremia and Sepsis, Fungemia","enrollment":300},{"nctId":"NCT06801119","phase":"NA","title":"Efficacy and Safety of HN2301 in Autoimmune Diseases（AIDs）","status":"RECRUITING","sponsor":"Shenzhen MagicRNA Biotechnology Co., Ltd","startDate":"2025-03-16","conditions":"Systemic Lupus Erythematosus, Scleroderma, Rheumatoid Arthritis","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Betaseron (beta interferon)","Copaxone (glatiramer acetate)","Aubagio (teriflunomide)","Extavia (beta interferon)","Gilenya (fingolimod)"],"phase":"marketed","status":"active","brandName":"Escalation Therapies Group","genericName":"Escalation Therapies Group","companyName":"The Cleveland Clinic","companyId":"the-cleveland-clinic","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Escalation Therapies Group involves gradually increasing the intensity of a treatment to achieve a desired therapeutic effect. Used for Treatment of various cancers.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}